ArticleHereditas2026
MicroRNA-345-3p expression inhibits colorectal cancer liver metastasis by targeting KHDRBS1 and TGF-β signaling pathway.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the association of microRNA-345-3p (miR-345-3p) with liver metastasis in colorectal cancer (CRC) and to explore its underlying molecular mechanisms using in vitro approaches.
methodsSerum specimens were collected from 110 CRC patients and 90 healthy individuals. Quantitative real-time PCR (qRT-PCR) was employed to assess the expression levels of miR-345-3p and KH RNA binding domain containing, signal transduction associated 1 (KHDRBS1) expression. The associations of miR-345-3p with clinical pathological characteristics, survival, and liver metastasis were analyzed. In vitro cell experiments were conducted to validate the effects of miR-345-3p on CRC cell growth and epithelial-mesenchymal transition (EMT). Target genes and signaling pathways were verified using luciferase reporter assays, rescue experiments, and Western blot analysis.
resultsA significant decrease in miR-345-3p expression was observed in CRC patients with liver metastasis. Low levels of miR-345-3p were correlated with advanced tumor node metastasis (TNM) stages, deeper invasion, lymph node metastasis, and poorer prognosis. Overexpression of miR-345-3p inhibited CRC cell growth and suppressed EMT-associated molecular changes. Bioinformatics analyses and experimental results confirmed KHDRBS1 as a direct target gene of miR-345-3p. Furthermore, rescue experiments demonstrated that overexpression of KHDRBS1 reverses the tumor-suppressive effects of miR-345-3p, indicating that miR-345-3p functions by regulating the transforming growth factor-β (TGF-β) signaling pathway.
conclusionsDecreased circulating levels of miR-345-3p are associated with liver metastasis in CRC. In vitro studies suggest that miR-345-3p may exert its tumor-suppressive effects by targeting KHDRBS1 and suppressing the TGF-β signaling pathway, thereby inhibiting CRC cell migration and invasive capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.